A recent approach to treating tuberculosis (TB) is offering hope for a simpler, more effective therapy. Researchers have developed an inhalable nanoparticle treatment for TB that could dramatically reduce the length and intensity of current regimens, potentially improving patient adherence and curbing the rise of drug-resistant strains. The findings, published in Antimicrobial Agents and Chemotherapy, detail a system for delivering the crucial TB drug rifampin directly to the lungs.
TB remains a global health crisis, responsible for an estimated 1.3 million deaths in 2022, according to the World Health Organization. While curable, the standard treatment involves months of multiple antibiotics, often causing significant side effects. These challenges frequently lead to patients discontinuing treatment, contributing to treatment failure and the development of drug-resistant TB, a particularly dangerous form of the disease.
Nanoparticle Delivery: Targeting the Lungs Directly
The research, led by Jessica L. Reynolds, associate professor of medicine at the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo, focuses on overcoming the limitations of oral rifampin. “Rifampin works well, but it has two major drawbacks when taken orally: It can damage the liver and not enough of the drug reaches the lungs, where TB bacteria live,” Reynolds explained. To address this, the team engineered a nanoparticle system designed for inhalation.
These nanoparticles aren’t simply carriers; they’re meticulously constructed to maximize their impact. According to Hilliard L. Kutscher, research assistant professor of medicine and first author on the study, the particles feature a biodegradable core containing rifampin, an outer coating to enhance adhesion to macrophages—immune cells where TB bacteria often hide—and a natural molecule on the surface to boost immune cell uptake and activity. “These particles are specially built to go straight to the lungs and be taken up by lung immune cells called macrophages,” Kutscher said. “They are designed to slowly release rifampin over time, to stimulate the immune system to better fight TB and to reduce drug exposure to the rest of the body, lowering side effects.”
Promising Results in Preclinical Trials
The potential of this new delivery method was tested in two different mouse models of TB, one representing a typical lung infection and the other mimicking the more severe lung damage seen in human cases. The study found that weekly inhaled nanoparticle treatments were as effective as—and in some cases, better than—daily oral rifampin in reducing the presence of Mycobacterium tuberculosis. The inhaled nanoparticles maintained higher concentrations of the drug in the lungs for an extended period—up to a week after a single dose—compared to oral administration.
Reynolds emphasized the importance of using both mouse models, stating, “Using both models makes the results more reliable and relevant to human disease.” All studies involving Mycobacterium tuberculosis were conducted in a certified Biosafety Level 3 (BSL-3) facility, ensuring adherence to stringent safety protocols for TB research.
Beyond Tuberculosis: Potential for Other Lung Infections
The implications of this research extend beyond TB. Rifampin is as well used to treat other serious lung infections caused by non-tuberculous mycobacteria, such as Mycobacterium kansasii and Mycobacterium xenopi, which are becoming increasingly common in the United States. Patrick O. Kenney, clinical assistant professor of pediatrics and a coauthor on the study, highlighted this broader potential.
Kenney also pointed out that the targeted lung delivery could resolve a significant drug interaction issue. Oral rifampin activates liver enzymes that can reduce the effectiveness of other crucial antibiotics, like azithromycin and clarithromycin, used to treat Mycobacterium avium/intracellulare complex (MAC) lung disease. “Given that of this interaction, rifampin is often avoided, even when it could otherwise facilitate,” Kenney explained. By delivering rifampin directly to the lungs, the researchers hope to minimize systemic exposure and reduce these harmful interactions.
Looking Ahead: Combination Therapies and Clinical Trials
The next phase of research will focus on integrating these nanoparticles with other standard TB antibiotics to create more comprehensive combination therapies, the current cornerstone of TB treatment. The team is optimistic that this inhalable approach will ultimately improve treatment adherence, reduce side effects, and increase access to care worldwide.
This research was funded by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. The development of new TB treatments is crucial, given the ongoing threat of drug-resistant strains and the need for more patient-friendly regimens. The potential for a once-weekly inhaled therapy represents a significant step forward in the fight against this deadly disease.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. This proves essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Share your thoughts on this promising new treatment in the comments below, and share this article with your network to spread awareness.
